Evidence map›Paper›PMID 40878038›Full record

ReviewCancer medicine2025

Boosting Dendritic Cell Function in Cancer.

Evangelos Giampazolias

Abstract readReview
In one paragraph

Review in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Evangelos GiampazoliasCancer Immunosurveillance Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0001-8013-3310

Funding

Cancer Research UK Institute Award C5759/A27412ERC Starting Grant 101165606Royal Society Research Grant RG\R2\232348
6 · The paper itself

Abstract

Instruction of T cell immunity is a key function of sentinel leukocytes called dendritic cells (DC). Several studies in mice and humans have demonstrated a key role for DCs in promoting T cell responses to cancer and augmenting the efficacy of T cell-based immunotherapies. Like other innate immune cells, DCs express a wide repertoire of receptors endowing them with the ability to detect microbial presence and tissue damage. These functions contribute to cancer immunity and have been previously linked to the induction of anti-tumour CD8

Indexed as

Dendritic CellsNeoplasmsAnimalsCD8-Positive T-LymphocytesHumansImmune Checkpoint InhibitorsImmunotherapyImmune Checkpoint Inhibitorsactivationantigen presentationcancer immunitydendritic cellsimmunotherapyT cell priming

Identifiers

PMID40878038
PMCPMC12394199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.